Patents Assigned to SmithKline Beecham Corporation
-
Patent number: 8252234Abstract: An apparatus is provided for producing pharmaceutical and pharmaceutical-like product. The apparatus provides real-time monitoring of the pharmaceutical product and can provide real-time control. The apparatus monitors the dosage both before and after it has been added to a carrier substrate. The apparatus can provide monitoring of each pharmaceutical product that is processed.Type: GrantFiled: June 9, 2005Date of Patent: August 28, 2012Assignee: SmithKline Beecham CorporationInventors: Allan J. Clarke, David George Doughty, Frederick H. Fiesser, David S. Wagner
-
Patent number: 8122849Abstract: An apparatus and method are provided for producing pharmaceutical and pharmaceutical-like products. The apparatus and method provide real-time monitoring of the pharmaceutical product and can provide real-time control. The apparatus and method can monitor the dosage both before and after it has been added to a carrier substrate. The apparatus and method can provide monitoring of each pharmaceutical product that is processed.Type: GrantFiled: June 9, 2005Date of Patent: February 28, 2012Assignee: SmithKline Beecham CorporationInventors: Allan J. Clarke, David George Doughty, Frederick H Fiesser, David Tainsh, Dwight Walker, David Wagner
-
Publication number: 20120045774Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.Type: ApplicationFiled: August 11, 2011Publication date: February 23, 2012Applicant: Smithkline Beecham CorporationInventors: Colin Houston MacPhee, David Graham Tew
-
Patent number: 8101244Abstract: An apparatus and method are provided for producing a plurality of products or processing a plurality of samples via dispensing. The apparatus and method provide real-time monitoring of the products/samples and can provide real-time control. The apparatus and method can monitor the liquid both before and after it has been added to a carrier substrate. The apparatus and method can provide monitoring of each product/sample that is processed.Type: GrantFiled: June 9, 2005Date of Patent: January 24, 2012Assignee: SmithKline Beecham CorporationInventors: Allan J. Clarke, David George Doughty, Frederick H. Fiesser
-
Patent number: 8022032Abstract: The method set out herein involves identifying the concentration of each of two or more active therapeutics tailored to treat a particular patient's unique metabolism and one or more diseases, communicating that information to a producer who has multiple fixed or variable concentrations of each active available, where the producer then combines the individual concentrations of each active into single units such as a tablets or pills, and distributes those indirectly or directly to the patient.Type: GrantFiled: November 18, 2005Date of Patent: September 20, 2011Assignee: SmithKline Beecham CorporationInventors: Richard L. Kirsh, Steven D. Finkelmeier, Robert Glinecke, Luigi Martini
-
Publication number: 20110144167Abstract: The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.Type: ApplicationFiled: August 21, 2009Publication date: June 16, 2011Applicant: SMITHKLINE BEECHAM CORPORATIONInventor: Rosanna Tedesco
-
Publication number: 20110124559Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.Type: ApplicationFiled: August 8, 2007Publication date: May 26, 2011Applicant: Smithkline Beecham CorporationInventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
-
Patent number: 7910321Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.Type: GrantFiled: September 23, 2008Date of Patent: March 22, 2011Assignees: Human Genome Sciences, Inc., SmithKline Beecham CorporationInventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz, Sally Doreen P. Lyn, Mark Hurle
-
Publication number: 20110053972Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.Type: ApplicationFiled: February 7, 2008Publication date: March 3, 2011Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Mark Andrew Seefeld, Meagan B. Rouse
-
Publication number: 20110034507Abstract: The present invention relates to farnesoid X receptors (FXR, NR1H4). FXR is a member of the nuclear receptor class of ligand-activate transcription factors. More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same. Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome.Type: ApplicationFiled: June 13, 2008Publication date: February 10, 2011Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Adwoa Akwabi-Ameyaw, David Norman Deaton, Robert Blount McFadyen, Frank Navas, III
-
Publication number: 20100330535Abstract: This disclosure relates to a composition and method for cleaning and polishing dentures during denture fabrication.Type: ApplicationFiled: February 20, 2009Publication date: December 30, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Prasad Adusimilli, Stanley J. Lech, Zvi G. Loewy
-
Patent number: 7858319Abstract: Methods of assessing the risk of clinical signs of hypersensitivity reaction to nucleoside antiviral compounds, including abacavir, are described. The methods include genotyping subjects for polymorphisms in the TNF? gene, the class 1 HLA genes, or a combination of both the TNF? and HLA genes.Type: GrantFiled: April 22, 2009Date of Patent: December 28, 2010Assignee: SmithKline Beecham CorporationInventors: Seth Hetherington, Arlene R Hughes, Eric H Lai, Michael Mosteller, Jr., Denise D Shortino
-
Publication number: 20100311775Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5, R6, R13, A, B, Y, Z, x, and m are defined herein, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.Type: ApplicationFiled: January 30, 2009Publication date: December 9, 2010Applicant: SmithKline Beecham CorporationInventors: Joseph Paul Marino, JR., John Jeffrey McAtee
-
Publication number: 20100273661Abstract: A method for predicting treatment response of a type II diabetes patient to rosiglitazone is provided. The method involves at least one sample from a patient having type II diabetes and analyzing biomarkers predictive of a patient who will respond to treatment with rosiglitazone. The biomarkers include, at least, interleukin-8, histidine, citrate. These biomarkers are identified in at least one classification analyses selected from the group consisting of a majority-vote based classifier and support-vector machine (SVM) classifier. Also provided is a method for predicting treatment response of a type II diabetes patient to glyburide at 8 weeks post-initiation of therapy. The method involves obtaining a sample from a type II diabetes patient who has been treated with glyburide for about 4 weeks and analyzing biomarkers predictive of a patient who will respond to treatment with glyburide at 8 weeks. The biomarkers useful in this method include, at least, sphingomyelin 23:1 and L-phenylalanine.Type: ApplicationFiled: June 11, 2008Publication date: October 28, 2010Applicants: SmithKline Beecham Corporation, BG Medicine IncInventors: Yang Qiu, Dilip Rajagopalan, Lei Zhu, Susan C Connor, Guanghui Hu, David Maclean, Doris Damian, Amir Handzel, Rajalakshmi Balasubramanian
-
Publication number: 20100272743Abstract: S epidermidis polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides and DNA (RNA) for the treatment of infection, particularly infections arising from S epidermidis. Antagonists against the function of such polypeptides and their use as therapeutics to treat infection are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of S epidermidis nucleic acid sequences and the polypeptides in a host.Type: ApplicationFiled: January 19, 2007Publication date: October 28, 2010Applicant: SmithKline Beecham CorporationInventor: William John Kimmerly
-
Publication number: 20100267759Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.Type: ApplicationFiled: February 7, 2008Publication date: October 21, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
-
Patent number: 7812016Abstract: The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.Type: GrantFiled: May 12, 2004Date of Patent: October 12, 2010Assignee: SmithKline Beecham CorporationInventor: Brian A. Johns
-
Publication number: 20100249179Abstract: The present invention provides novel isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.Type: ApplicationFiled: June 13, 2008Publication date: September 30, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: David Norman Deaton, Frank Navas, III, Paul Kenneth Spearing
-
Publication number: 20100240642Abstract: The present invention relates to certain indole derivatives that are modulators of PPAR?, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.Type: ApplicationFiled: August 31, 2007Publication date: September 23, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Jeffrey Alan Oplinger, Paul Kenneth Spearing, Millard Hurst Lambert, John A. Ray, Christopher P. Laudeman, Jerzy R. Szewczyk, Pierette Banker
-
Patent number: D662203Type: GrantFiled: June 20, 2011Date of Patent: June 19, 2012Assignee: SmithKline Beecham CorporationInventor: David William Smith